{"id":5665,"date":"2023-09-04T03:16:22","date_gmt":"2023-09-04T03:16:22","guid":{"rendered":"https:\/\/cm.vastapps.dev\/tcia-collection\/qin-prostate\/"},"modified":"2023-09-13T12:02:11","modified_gmt":"2023-09-13T12:02:11","slug":"qin-prostate","status":"publish","type":"tcia_collection","link":"https:\/\/cm.vastapps.dev\/tcia-collection\/qin-prostate\/","title":{"rendered":"QIN-PROSTATE"},"featured_media":0,"template":"","citation-tax":[],"cancer_types":["Prostate Cancer"],"citations":[4595,4596,4597,2925],"collection_doi":"10.7937\/K9\/TCIA.2016.fADs26kG","collection_download_info":"When you have a TCIA account, please email to\u00a0help@cancerimagingarchive.net<\/a>\u00a0to request access to these data.\n\nClick the Versions tab for more info about data releases.","collection_downloads":[5210],"full_export":"

Summary<\/h2>

This collection contains multiparametric MRI images collected for the purposes of detection and\/or staging of prostate cancer. The MRI parameters include T1- and T2-weighted sequences as well as Diffusion Weighted and Dynamic Contrast-Enhanced MRI. The images were obtained using endorectal and phased array surface coils at 3.0T (GE Signa HDx 15.0) The value of this collection is to provide clinical image data for the development and evaluation of quantitative methods for prostate cancer characterization using multiparametric MRI.\u00a0 Data was provided by Brigham and Women's Hospital, PI Dr. Fiona Fennessy.<\/span>MR imaging exam was performed on a GE Signa HDx 3.0\u00a0T magnet (GE Healthcare, Waukesha, WI) using a combination of 8-channel abdominal array and endorectal coil (Medrad, Pittsburgh, PA). The MR sequences included\u00a0T<\/em>1<\/sub><\/em>- and\u00a0T<\/em>2<\/sub><\/em>-weighted imaging, diffusion weighted (DW) imaging, and DCE MRI.\u00a0T<\/em>1<\/sub><\/em>-weighted imaging was performed with a spoiled gradient recalled echo (SPGR) sequence with TR\/TE\/\u03b1\u00a0=\u00a0385\u00a0ms\/6.2\u00a0ms\/65\u00b0 over a (16\u00a0cm)2<\/sup>\u00a0field of view (FOV).\u00a0T<\/em>2<\/sub><\/em>-weighted imaging was performed with a FRFSE (Fast Recovery Fast Spin Echo) sequence with TR\/TE\u00a0=\u00a03500\/102\u00a0ms, FOV\u00a0=\u00a0(16\u00a0cm)2<\/sup>. A DW echo planar imaging sequence with trace diffusion sensitization and\u00a0b<\/em>-values of 0 and 500\u00a0s\/mm2<\/sup>, and TR\/TE\u00a0=\u00a02500\/65\u00a0ms provided data for an Apparent Diffusion Coefficient (ADC) map. Finally, DCE MRI utilized a 3D SPGR sequence with TR\/TE\/\u03b1\u00a0=\u00a03.6\u00a0ms\/1.3\u00a0ms\/15\u00b0, FOV\u00a0=\u00a0(26\u00a0cm)2<\/sup>, with full gland coverage and reconstructed image voxel size of 1\u00d71\u00d76\u00a0mm (interpolated to 256\u00d7256 matrix). DCE MRI frames were acquired at approximately 5\u00a0s intervals (the number of frames varied between 12 and 16 slices resulting in the time resolution between 4.4 and 5.3\u00a0seconds) to achieve a clinically appropriate compromise between spatial and temporal resolutions. Gadopentetate dimeglumine (Magnevist, Berlex Laboratories, Wayne, New Jersey) was injected intravenously using a syringe pump (0.15\u00a0mmol\/kg) at the rate of 3\u00a0ml\/s followed by 20\u00a0ml saline flush at the same rate. The protocol included ~\u00a05 baseline scans prior to contrast injection for estimation of baseline tissue properties.<\/p>

About the NCI QIN<\/h4>

The mission of the QIN is to improve the role of quantitative imaging for clinical decision making in oncology by developing and validating data acquisition, analysis methods, and tools to tailor treatment for individual patients and predict or monitor the response to drug or radiation therapy. More information is available on the Quantitative Imaging Network Collections<\/a> page. Interested investigators can apply to the QIN at: Quantitative Imaging for Evaluation of Responses to Cancer Therapies (U01) PAR-11-150<\/a>.<\/p>

<\/p>